Schifferdecker E, Jungmann E, Schöffling K
Fortschr Med. 1989 May 20;107(15):348-50.
Twenty diabetics conventionally treated with Depot H and/or Basal H Insulin Hoechst received the OptiPen as an injection aid for the corresponding U100 insulin preparations. Seventeen patients had such a positive opinion of the pen, that they wanted to continue using it. After 15.6 +/- 5.3 weeks of "pen therapy", the mean insulin dose remained unchanged. In the 14 patients who had been treated with insulin long before the change over to the pen, the mean HbA1 level showed no change (8.8 +/- 1.2% before versus 8.7 +/- 1.5% under pen therapy). The use of an injection aid--in this case the OptiPen--facilitates insulin therapy for the usually older diabetics treated with intermediate acting or mixed insulin, too. Technical problems over the long term were not encountered and the quality of metabolic control remained unchanged.
20名常规使用德普特H胰岛素和/或赫斯特基础H胰岛素治疗的糖尿病患者接受了OptiPen作为相应U100胰岛素制剂的注射辅助工具。17名患者对该笔持积极看法，希望继续使用。经过15.6±5.3周的“笔式治疗”后，平均胰岛素剂量保持不变。在改用笔式治疗之前长期接受胰岛素治疗的14名患者中，平均糖化血红蛋白水平没有变化（改用笔式治疗前为8.8±1.2%，笔式治疗期间为8.7±1.5%）。使用注射辅助工具——在这种情况下是OptiPen——也便于通常使用中效或混合胰岛素治疗的老年糖尿病患者进行胰岛素治疗。未遇到长期技术问题，代谢控制质量保持不变。
